Literature DB >> 8916122

MIB-1 immunostaining and DNA flow cytometry in meningiomas.

M Yasue1, Y Akasaki, T R Numoto, S Abe, T Abe, Y Takeuchi, J Tanaka.   

Abstract

The correlation between S- and G2/M-phase fractions and MIB-1 index in meningiomas was investigated. Flow cytometric analyses were performed on cell suspensions from 81 samples of paraffin-embedded tissue from 29 patients with a total of 28 meningiomas and 1 hemangiopericytoma using the modified Hedley's method. Sections from the paraffin-embedded tissues were stained with anti-MIB-1 monoclonal antibody after microwave oven processing. Five hundreds cells were scored. Correlations between data were estimated using linear regression. DNA aneuploidy was present in 4/29 tumors. Mean S- and G2/M-phase fractions in the 25 nonrecurrent tumors were 1.77 and 4.76%, and in the recurrent tumors were 2.41 and 5.81%, respectively. The proliferative index (PI = S + G2/M fraction) was 6.52% in the nonrecurrent tumors and 8.29% in the recurrent tumors. The mean MIB-1 score in the nonrecurrent tumors was 1.25% and in the recurrent tumors was 2.69%. There was a linear correlation between percentage of S-phase fraction or PI and the MIB-1 score. Both methods are useful to assess the proliferative activity in meningioma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916122

Source DB:  PubMed          Journal:  Noshuyo Byori        ISSN: 0914-8108


  2 in total

1.  Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics.

Authors:  Paulo Henrique Aguiar; Ana Maria Tsanaclis; Oswaldo Inácio Tella; José Pindaro Plese
Journal:  Neurosurg Rev       Date:  2003-04-08       Impact factor: 3.042

2.  Intraoperative quantification of meningioma cell proliferation potential using rapid flow cytometry reveals intratumoral heterogeneity.

Authors:  Soichi Oya; Shinsuke Yoshida; Tsukasa Tsuchiya; Naoaki Fujisawa; Akitake Mukasa; Hirofumi Nakatomi; Nobuhito Saito; Toru Matsui
Journal:  Cancer Med       Date:  2019-04-16       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.